Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

HiQ DEVELOPS THE COMMUNICATION WHEN MATCH CUP SWEDEN RENEWS ITSELF

The Match Cup Sweden  sailing competition is one of Sweden’s largest sports events with around 100,000 visitors every summer. For this year’s sailing regatta on 4-9 July, almost everything is renewed – from the boats to a record-breaking prize sum. HiQ is in charge of the communication, yet another step in a successful partnership.“We’re happy and proud to have earned the trust to create a completely new concept for communication, including advertisements, radio commercials, graphic profile, and digital communication. We have worked with Match Cup Sweden for a

European Directories acquires Busymouse and repurchases own bonds

Dogado GmbH (“Dogado”), a 61% owned European Directories Group company, has acquired 100% of the shares in BUSYMOUSE Business Systems GmbH, a German company providing hosted exchange and cloud services through more than 700 IT channel partners to German SME customers. This acquisition reinforces Dogado’s strategy to become a leading cloud services provider in Germany. Further, European Directories (DH7) B.V., also a European Directories Group company, has recently purchased TEUR 13,048 nominal value of the bonds issued by European Directories BondCo S.C.A. for a consideration of TEUR 6,

Change in number of shares and votes in Moberg Pharma

STOCKHOLM, June 30, 2016. The number of shares and votes in Moberg Pharma AB (publ) has increased by 71,666 to 14,289,188 during June 2016. Therefore, there are in total 14,289,188 shares and votes in the company as of June 30, 2016.The reason for the increase is that warrants in Moberg Pharma have been exercised under the company’s share-based incentive program. About this information               Moberg Pharma discloses this information pursuant to the Swedish Securities Markets Act and/or the Financial Instruments Trading Act. The information was submitted for publication at 8.30 a.

Increase in the number of shares in Hoist Finance AB (publ) through exercise of warrants

Exercise of warrants has been registered in June 2016 and as a result Hoist Finance AB (publ)’s share capital has increased by SEK 65,820 to SEK 26,276,291.33. The total number of shares has increased by 197,460 whereby it now amounts to 78,828,874 shares. The total number of voting rights amounts to 78,828,874. For further information please contact: Michel Jonson, Group Head of Investor Relations Telephone: +46 (0)8 555 177 19 The information above has been published pursuant to the Swedish Securities Markets Act (Sw. lagen om värdepappersmarknaden) and/or the Swedish

Change in number of shares outstanding in Sectra during June

Linköping, Sweden, June 30, 2016 – As of June 30, 2016, the number of shares in Sectra AB (STO: SECT B) totals 37,686,105. This means that in June, the number of shares outstanding increased by 182,770.The change was attributable to a new share issue in connection with the conversion of Sectra’s convertible debenture programs 2011/2016 and 2012/2016. The number of shares after the change is distributed as follows: ·  2,620,692 ordinary Class A shares. ·  35,065,413 ordinary Class B shares. The Class A share carries ten votes and the Class B share one vote. The information

Increase in number of shares in Avanza

As earlier announced the number of shares outstanding in Avanza Bank Holding AB (publ) (“the Company”) has increased with 27,721 due to the completed share issue as a result of the exercise of employee warrants. The warrants exercised are part of the incentive programme decided by the Annual General Meeting held on April 14, 2011. The share capital increases consequently to SEK 74,597,305. As of June 30 there are in total 29,838,922 shares in the Company. The shares entitle the holder to equal number of votes. “This information is such that Avanza Bank Holding AB (publ) is obliged to

Genovis and Promega sign global license agreement and settle litigation

Genovis has reached a settlement in its patent infringement lawsuit with Promega Corp. and agreed to a royalty bearing, worldwide license to the patents-in-suit.The settlement ends all ongoing patent-infringement claims between the parties and Promega has agreed to a royalty bearing, worldwide license to the patents-in-suit, thereby ending the lawsuit between the parties. The specific terms of the contract are confidential. “I am pleased we were able to reach a settlement with a favorable business solution that accommodates Genovis’ long term growth strategy,” says Fredrik Olsson, CEO of

Adelis creates Danish market leader in IT outsourcing by merging IT Relation, Front-data and DSI-NEXT

Adelis Equity Partners (“Adelis”) has acquired majority stakes in IT Relation, Front-data and DSI-NEXT. The companies’ management teams continue as minority shareholders in the new setup.The combined businesses will be the largest provider of IT outsourcing services to small businesses in Denmark with around DKK 300 million in revenues, 200 employees and offices in Herning, Århus, Odense and Copenhagen. ”With the combination of IT Relation, Front-data and DSI-NEXT, we have made four investments and three add-on acquisitions in Denmark since establishing Adelis less than three years ago.

NOBINA CELEBRATES ONE YEAR ON THE EXCHANGE WITH NEW RECORD PROFIT

THE FIRST QUARTER  • Net sales amounted to SEK 2,224 million (1,995), an increase of 11.5 per cent. • Operating profit was SEK 121 million (14). The adjusted operating profit for the first quarter of last year was SEK 106 million before listing expenses. • Profit for the period after tax amounted to SEK 69 million (–33) and profit per share amounted to SEK 0.78 (–0.52). The adjusted profit after tax for the first quarter of last year was SEK 59 million before IPO expenses. • Cash flow from the operations was SEK 268 million (156). • The cash flow was SEK 32 million (–38). The

Increased number of shares and votes in Castellum

As previously announced, Castellum AB (publ) has carried out a rights issue of 82,000,000 shares, a new issue of 19,194,458 shares against payment in kind and a transfer of 8,006,708 repurchased shares. The company’s share capital as well as number of registered and outstanding shares and votes have, therefore, increased in June 2016. As of June 30, 2016, the total number of registered and outstanding shares in Castellum AB (publ) amount to 273,201,166, corresponding to 273,201,166 votes. The rights issue and the new issue of shares against payment in kind have increased the company’s

New number of shares in Handelsbanken

Due to an exchange of convertible notes in Svenska Handelsbanken AB, the number of Class A shares has increased by 3 724 802 shares and the number of votes has increased by 3 724 802. Following the increase, the total number of shares in Handelsbanken is 1 935 847 037 of which 1 900 595 708 are Class A shares and 35 251 329 are Class B shares. The total number of votes in Handelsbanken is 1 904 120 840,90. The share capital amounts to SEK 3 000 562 907,35 after the increase. The information is that which must be made public according to the Swedish Financial Instruments Trading Act. The

Change in the total number of shares and votes in Recipharm AB (publ)

As of 30 June 2016, the total number of shares in Recipharm AB (publ) (“Recipharm”) amounts to 63,217,532 shares, divided into 15,222,858 shares of series A, 47,494,674 shares of series B and 500,000 shares of series D. The total number of votes in Recipharm as of 30 June 2016 amounts to 200,223,254.As previously announced by Recipharm, the number of shares and votes in Recipharm has increased as a result of a cash issue of 2,537,142 shares of series A and 7,273,924 shares of series B with preferential rights for the shareholders of the Company in the amount of approximately SEK 805 million,

SAS sells minority holding in Widerøe

In September 2013, SAS sold 80% of the shares in Widerøe AS (Widerøe) to WF Holding AS (WF Holding), an investment company controlled by Torghatten ASA. At the same time SAS informed that the remaining shares would be divested during 2016. SAS has now together with the WF Holding agreed to sell the remaining holding of 20% to WF Holding according to the sales agreement. The shares are transferred on 30 June 2016. The transfer of shares will not affect SAS’s earnings or cash position during fiscal year 2015/2016. Widerøe will continue to be a regional partner to SAS. SAS Investor

Orexo signs license agreement with Mundipharma, which obtains ex-US global rights to Zubsolv®

Uppsala, Sweden - June 30, 2016 - Orexo AB (publ.) today announced an agreement granting Mundipharma’s network of independent associated companies´ exclusive global (ex-US) rights to Zubsolv® (buprenorphine and naloxone) sublingual tablet (CIII), for treatment of opioid dependence. Under the terms of the agreement Orexo receives an upfront payment of 7 million euros. Pending marketing authorizations and commercial milestones Orexo is also entitled to receive further milestone payments and up to low double digit royalties on future net sales. Orexo will also be compensated for specific

Pandox AB (publ) and Scandic Hotels renew leases for 19 hotels in the Nordic region

The hotel property company Pandox and the hotel operator Scandic Hotels have renewed and extended lease agreements for 19 hotels in the Nordic region. The lease agreements have a duration of up 15 years and include a joint renovation programme of MSEK 470 over three years, of which Pandox’s share amounts to approximatelyhalf. “Scandic Hotels have successfully operated the hotels over a long period of time and we are pleased to be able to present an extension of the lease agreements. With renewed leases and joint investments we are strengthening both our strategic partnership and joint

Moberg Pharma enters into a definitive agreement to acquire three U.S. OTC brands from Prestige Brands

STOCKHOLM, June 30, 2016. Moberg Pharma AB (OMX: MOB) has signed an agreement to acquire New Skin®, Fiber Choice® and PediaCare®, three well-established Over-The-Counter brands in the U.S. from Prestige Brands, Inc. In the latest 12 months ending March 31, 2016, the Net sales of these brands was approximately $24.4 million. The purchase price is $40 million and Moberg Pharma expects the acquired brands to contribute to its EBITDA with approximately $5 million for the 12 months following closing of the transaction. The acquisition is financed by available cash resources and a tap issue to

Change in number of shares in Wilson Therapeutics

The number of shares and votes in Wilson Therapeutics AB (publ) has changed as a result of the new issue of shares that was made based on the over-allotment option granted in connection with the listing of the company’s shares on Nasdaq Stockholm. Today, the last trading day of the month, there are in total 25,720,248 shares and votes in Wilson Therapeutics. About Wilson TherapeuticsWilson Therapeutics is a biopharmaceutical company, based in Stockholm, Sweden, that develops novel therapies for patients with rare diseases. Wilson Therapeutics’ lead product, Decuprate®, is initially

Conference call to present the financial results for the second quarter and first six months 2016

Qliro Group AB (publ) will publish its financial results for the second quarter and first six months 2016 on Thursday 14 July 2016 at 08.00 CET. A conference call will be held the same day at 10.00 CET.The conference call will be hosted by Paul Fischbein, Chief Executive Officer of Qliro Group, and Nicolas Adlercreutz, Chief Financial Officer. To participate in the conference call, please register by using the link below, the dial-in details for the conference call will be made available upon registration:www.qlirogroup.com/conferencecallThe conference call will also be webcasted in ‘

Property transactions completed during the second quarter 2016

Apart from the previously communicated transactions, Wallenstam sold and vacated five properties during the quarter, with an agreed property value of SEK 513 million.“We have a plan to gradually rejuvenate our property holdings, primarily through new construction of quality rental apartments. I am pleased to confirm that we are now involved in several major and exciting urban development projects in both Stockholm and Gothenburg, for example Umami, Kallebäcks Terrasser and Älta, to mention a few,” says Hans Wallenstam, CEO of Wallenstam. “The plan above also means that we sometimes

Scandic enters another long-term strategic agreement with Pandox

– renovating and prolonging leases for 19 hotels in the NordicsScandic Hotels, the leading hotel company in the Nordic countries, and the property company Pandox have agreed to prolong the leases for 19 hotels in the Nordic region and to start a renovation program at the hotels. The investment amounts to 470 MSEK over a three-year period that will be divided equally between the parties. Scandic and Pandox have agreed to extend the leases for 19 hotels in the Nordic countries, including eight in Sweden, six in Finland, three in Denmark and two in Norway with the majority of the lease

Heliospectra Receives Over Half a Million USD Order of LED Grow Lights

Heliospectra AB (publ) (OTCQB: HLSPY, FIRSTNORTH: HELIO), a world leader in intelligent lighting technology for controlled environments horticulture, is proud to announce that an order valued at 0.54 MUSD (4.6 MSEK) has been received from a Fortune 500 Ag-Tech company located in the USA.This order adds to a previous order from 2015 bringing the total light count to over 700 Heliospectra's high efficiency E60 LED grow lights. The customer chose to invest in Heliospectra LED grow lights for their greenhouses based on the high quality light output and overall product reliability. Greenhouse

New research data with C21 on diabetes

- Dr Chow et al, Melbourne: C21 has an anti-aterosclerotic effect in animal models with diabetes. - Dr Liu et al, Beijing: C21 protects the pancreas against damages caused by high fat intake.Dr Bryna Chow and co-workers, from the internationally renowned research group at Baker Institute in Melbourne, have studied the effects of C21 on mechanisms involved in the atherosclerotic process in a diabetic animal model. The results were recently published on-line in the journal ‘Diabetologia’ In this study, biomarkers of inflammation and oxidative stress (free radicals) in the vascular wall

Ericsson and KDDI partner to deliver Internet of Things connectivity to enterprises

· KDDI utilizes Ericsson Device Connection Platform to offer Internet of Things connectivity services to enterprise customers · DCP enables KDDI customers to deploy, manage and scale IoT connected devices and applications globally · Ericsson forecasts 16 billion IoT connected devices by 2021 Ericsson (NASDAQ: ERIC) today announces a partnership with KDDI, a leading Japanese operator, to deploy Ericsson Device Connection Platform (DCP). The partnership will provide enhanced connectivity services to KDDI's enterprise customers and support the deployment of IoT solutions on a global

There are no items matching the current filter
There are no more items matching the current filter
Back to top